Every Form 4 that Clorox Co Del (CLX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLX filings page.
Matthew J. Shattock, a director of Clorox Co. (CLX), reported two grants of Deferred Stock Units (DSUs) that increase his notional holdings. On 08/29/2025 he received 172.9087 DSUs through dividend reinvestment, and on 09/30/2025 he received 415.6529 DSUs in lieu of quarterly director fees.
The report shows DSUs convert on a 1-for-1 basis into common stock at the director's retirement or termination and that the total DSUs after the September grant equal 17,070.6618 shares. Both grants are reported as direct beneficial ownership and have a $0.00 per-unit price because they are deferred compensation awards.
Clorox director Stephanie Plaines reported two grants of Deferred Stock Units (DSUs) that increase her beneficial ownership. On 08/29/2025 she received 53.9884 DSUs through dividend reinvestment, and on 09/30/2025 she received 212.8954 DSUs in lieu of quarterly director fees. The filing shows the DSUs will be settled 100% in Clorox common stock upon the reporting person’s retirement or other termination, and total reported beneficial ownership after the transactions is 5,413.1984 shares (previously 5,200.303).
Spencer C. Fleischer, a director of Clorox Co. (CLX), reported two acquisitions of deferred stock units under the board’s deferred compensation plan. On 08/29/2025 he received 192.9623 deferred stock units through dividend reinvestment and on 09/30/2025 he received 212.8954 units in lieu of quarterly director fees. The filing states the deferred stock units will be settled 1-for-1 in Clorox common stock upon the reporting person’s retirement or termination. Following the reported transactions, the filing shows total beneficial ownership of 18,799.5242 common shares.
Pierre R. Breber, a Director of Clorox Co. (CLX), reported transactions showing continued ownership and receipt of deferred compensation units. The filing shows indirect ownership of 9,000 shares through a family trust. On 08/29/2025 he acquired 502.2399 deferred stock units via dividend reinvestment under the Independent Directors' Deferred Compensation Plan, and on 09/30/2025 he received 263.5848 deferred stock units in lieu of quarterly director fees. The report states the deferred stock units are 1-for-1 and "will be settled 100% in Clorox stock" upon the reporting person's retirement or other termination of service as a Director. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Laurene E. Peck, Vice President, Chief Accounting Officer & Corporate Controller of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 1,441 shares of common stock via restricted stock units at an attributable price of $124.85 per share. After the transaction Ms. Peck beneficially owned 5,821 shares directly and 100 shares indirectly through a trust of a parent. The restricted stock units vest in four equal installments on October 5 of 2026, 2027, 2028 and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
Stacey Grier, EVP & Executive Chief of Staff at The Clorox Company (CLX), reported an acquisition of 3,364 restricted stock units on 09/16/2025. The Form 4 shows the units were recorded at a price of $124.85 and, after the transaction, Ms. Grier beneficially owned 23,190 shares. The restricted stock units vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028 and 2029. The filing was signed by an attorney-in-fact on 09/18/2025.
Angela C. Hilt, Executive Vice President and Chief Legal Officer of The Clorox Company (CLX), reported an acquisition of 7,048 shares of Clorox common stock on 09/16/2025 at a reported price of $124.85 per share. After the reported transaction she beneficially owns 26,881 shares directly. The filing also discloses indirect ownership of 609.663 shares held via the company 401(k) plan. The acquired shares are described as Restricted Stock Units that will vest in four equal installments on October 5 of 2026, 2027, 2028 and 2029.
Marriner Kirsten, Executive Vice President and Chief Administrative Officer of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 7,689 shares of Clorox common stock at an average price of $124.85 per share, increasing her direct beneficial ownership to 33,994 shares. The filing is a single-person Form 4 signed by an attorney-in-fact on 09/18/2025. The report also discloses that the related Restricted Stock Units will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029.
Chris T. Hyder, EVP—Group President, Health & Hygiene at The Clorox Company (CLX), reported an equity award conversion on 09/16/2025. The filing shows the acquisition of 7,208 shares of Clorox common stock at an indicated price of $124.85 per share, bringing his total beneficial ownership to 29,325 shares. The shares arise from Restricted Stock Units that vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028 and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025. This disclosure records an insider share increase tied to compensation rather than an open-market purchase.
Nina Barton, Executive Vice President and Group President - Care & Connections at The Clorox Company (CLX), reported an acquisition on 09/16/2025 of 7,208 shares of Clorox common stock at a reported price of $124.85 per share, increasing her beneficial ownership to 28,496 shares. The filing indicates these shares are restricted stock units that will vest in four equal installments on October 5 of 2026, 2027, 2028, and 2029. The Form 4 was submitted by attorney-in-fact Jinho Joo on 09/18/2025.
Eric H. Reynolds, EVP and Chief Operating Officer of The Clorox Company (CLX), reported an acquisition of company common stock on 09/16/2025. The Form 4 shows an acquisition of 9,611 shares at a price of $124.85 per share, bringing his beneficial ownership to 63,832 shares following the transaction. The filing also discloses Restricted Stock Units that vest in four equal installments on October 5 of 2026, 2027, 2028, and 2029. The form was signed by an attorney-in-fact on 09/18/2025.
Luc Bellet, EVP and Chief Financial Officer of The Clorox Company (CLX), reported an open-market purchase of 7,368 shares of Clorox common stock on 09/16/2025 at a reported price of $124.85 per share. After the purchase, the filing shows Mr. Bellet beneficially owned 19,546 shares. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
The filing also discloses restricted stock units that will vest in four equal installments on October 5, 2026, October 5, 2027, October 5, 2028, and October 5, 2029. No derivative transactions, dispositions, or additional cash- or price-related terms beyond the reported purchase price are included in the document.
Linda J. Rendle, Chief Executive Officer and Director of The Clorox Company (CLX), reported an award of 34,281 shares of Common Stock on 09/16/2025 at a reported price of $124.85 per share, increasing her beneficial ownership to 167,537 shares. The filing indicates these shares are Restricted Stock Units that will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.